Click on a filter below to refine your search. Remove a filter to broaden your search.
Merck says the vaccine covers serotypes responsible for approximately 84% of invasive pneumococcal disease in adults aged 50 or more years.
Vaccine uptake by senior living residents is being hampered by barriers to access, vaccine fatigue and misinformation, according to two providers.